ACE-2-derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2
SARS-CoV-2, a novel coronavirus causing overwhelming death and infection worldwide, has emerged as a pandemic. Compared to its predecessor SARS-CoV, SARS-CoV-2 is more infective for being highly contagious and exhibiting tighter binding with host angiotensin-converting enzyme 2 (hACE-2). The entry of the virus into host cells is mediated by the interaction of its spike protein with hACE-2. Thus, a peptide that has a resemblance to hACE-2 but can overpower the spike protein-hACE-2 interaction will be a potential therapeutic to contain this virus. The non-interacting residues in the receptor-binding domain of hACE-2 have been mutated to generate a library of 136 new peptides. Out of this library, docking and virtual screening discover seven peptides that can exert a stronger interaction with the spike protein than hACE-2. A peptide derived from simultaneous mutation of all the non-interacting residues of hACE-2 yields two-fold stronger interaction than hACE-2 and thus turns out here to be the best peptide-inhibitor of the novel coronavirus. The binding of the spike protein and the best peptide-inhibitor with hACE-2 is explored further by molecular dynamics, free energy, and principal component analysis to demonstrate its efficacy. Further, the inhibition assay study with the best peptide inhibitor is in progress..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
chemRxiv.org - (2021) vom: 17. Nov. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Panda, Saroj Kumar [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
doi: |
10.26434/chemrxiv.12335933 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XCH017931657 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XCH017931657 | ||
003 | DE-627 | ||
005 | 20230429143359.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200525s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.26434/chemrxiv.12335933 |2 doi | |
035 | |a (DE-627)XCH017931657 | ||
035 | |a (chemrXiv)10.26434/chemrxiv.12335933 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Panda, Saroj Kumar |e verfasserin |4 aut | |
245 | 1 | 0 | |a ACE-2-derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2 |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a SARS-CoV-2, a novel coronavirus causing overwhelming death and infection worldwide, has emerged as a pandemic. Compared to its predecessor SARS-CoV, SARS-CoV-2 is more infective for being highly contagious and exhibiting tighter binding with host angiotensin-converting enzyme 2 (hACE-2). The entry of the virus into host cells is mediated by the interaction of its spike protein with hACE-2. Thus, a peptide that has a resemblance to hACE-2 but can overpower the spike protein-hACE-2 interaction will be a potential therapeutic to contain this virus. The non-interacting residues in the receptor-binding domain of hACE-2 have been mutated to generate a library of 136 new peptides. Out of this library, docking and virtual screening discover seven peptides that can exert a stronger interaction with the spike protein than hACE-2. A peptide derived from simultaneous mutation of all the non-interacting residues of hACE-2 yields two-fold stronger interaction than hACE-2 and thus turns out here to be the best peptide-inhibitor of the novel coronavirus. The binding of the spike protein and the best peptide-inhibitor with hACE-2 is explored further by molecular dynamics, free energy, and principal component analysis to demonstrate its efficacy. Further, the inhibition assay study with the best peptide inhibitor is in progress. | ||
650 | 4 | |a Chemistry |7 (dpeaa)DE-84 | |
650 | 4 | |a 540 |7 (dpeaa)DE-84 | |
700 | 1 | |a Gupta, Parth Sarthi Sen |e verfasserin |4 aut | |
700 | 1 | |a Biswal, Satyaranjan |e verfasserin |4 aut | |
700 | 1 | |a Ray, Abhik Kumar |e verfasserin |4 aut | |
700 | 1 | |a Rana, Malay Kumar |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t chemRxiv.org |g (2021) vom: 17. Nov. |
773 | 1 | 8 | |g year:2021 |g day:17 |g month:11 |
856 | 4 | 0 | |u https://doi.org/10.1021/acs.jproteome.0c00686 |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.26434/chemrxiv.12335933 |z kostenfrei |3 Volltext |
912 | |a GBV_XCH | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 17 |c 11 |